Clinical Trial Update: Efficacy and Safety Study of p144 to Treat Skin Fibrosis in Systemic Sclerosis [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating p144 for skin fibrosis in systemic sclerosis has completed, reporting efficacy and safety data. The sponsor is ISDIN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis

Drugs mentioned

• p144

Snippet

Sponsor: ISDIN | Conditions: Skin Fibrosis | Phase 2 | Status: COMPLETED